New York, Jan 27, 2026, 05:34 EST — Premarket
- BiomX (PHGE) surged roughly 65% in premarket trading following a disclosure revealing a fresh investor with nearly a 20% stake
- Pyu Pyu Capital and its managing member disclosed a 19.99% stake in a Schedule 13D filing
- Traders are focused on a shareholder vote and the registration steps linked to the deal that established the stake
BiomX Inc shares jumped roughly 65% to $6.77 in premarket action Tuesday, even hitting $8.34 earlier, after news surfaced that a new investor snapped up nearly a 20% stake.
This matters since BiomX is a microcap biotech with a thin tape. With one major holder hovering just below a crucial exchange threshold, the stock can jump sharply and then swing wildly.
The timing couldn’t be worse for the company. Investors are zeroed in on cash flow and control—who’s ready to back the business, and on what terms.
A Schedule 13D filing revealed that Pyu Pyu Capital, LLC and its managing member Reuven Yeganeh now hold a 19.99% beneficial stake, linked to a $3.0 million private placement. According to the filing, BiomX issued 3,300 shares of Series Y convertible preferred stock, valued at $3.3 million, along with warrants for 3.3 million common shares. The preferred shares carry a 15% annual dividend and mature one year after the Jan. 13 closing, while the warrants have a $2.00 exercise price and a five-year term. BiomX also committed to convene a shareholder meeting within 60 days post-closing to seek approval for issuing more than 19.99% of its common stock under NYSE American rules. Additionally, the company agreed to file a resale registration statement within 30 days of closing, the document showed.
According to the filing, the conversion and exercise prices may reset lower following shareholder approval, tied to the stock’s closing price near the vote. Until that happens, the investor cannot convert or exercise if it would raise their beneficial ownership beyond 19.99%.
BiomX focuses on bacteriophage therapies—using viruses that target bacteria—with programs targeting cystic fibrosis and inflammatory bowel disease. The company reported $8.1 million in cash as of Sept. 30, enough to fund operations through Q1 2026, according to its latest update.
BiomX’s stock has swung sharply since December, when the company announced it was halting its Phase 2b BX004 cystic fibrosis trial. The move came after an internal review and input from its data monitoring committee.
The financing setup cuts both ways for common shareholders. With preferred stock dividends, a one-year maturity, and the chance of conversion at a lower effective price, dilution risk climbs—particularly if the company seeks additional capital.
Another question mark: the shareholder vote. If it’s postponed or rejected, the investor’s chance to convert and exercise stays limited, pushing back registration and resale deadlines.
Traders will be watching if the premarket spike sticks once volume ramps up after the open, and whether BiomX acts swiftly to schedule the shareholder meeting mandated by the deal—set for mid-March—while also tackling the resale registration deadline looming mid-February.
